

30 pieces
Aromasin is an antitumor agent inhibiting the synthesis of estrogen. It blocks aromatase and stops the synthesis of estrogen (without affecting the production of other steroid hormones, such as cortisol and aldosterone).
Common breast cancer in women in natural or induced postmenopause with the progression of the disease on the background of anti-estrogenic therapy, as well as with the progression of the disease after repeated use of various types of hormonal therapy;
adjuvant treatment of early breast cancer in postmenopausal women with estrogen-positive receptors or with unknown receptor status, after completion of 2-3 years of initial adjuvant therapy with Tamoxifen, in order to reduce the risk of recurrence (remote or regional), as well as contralateral breast cancer.
Hypersensitivity to exemestane or to any other component of aromazine; premenopausal endocrine status; pregnancy and lactation; childhood.With caution - a violation of the liver or kidneys.
Inside, preferably after a meal. Adults and elderly patients - 25 mg Aromasin 1 time per day.
On the part of the digestive system: very often - nausea; often - anorexia, abdominal pain, vomiting, constipation, dyspepsia, diarrhea.
From the central and peripheral nervous system: very often - insomnia, headache; often - depression, dizziness, carpal tunnel syndrome.
On the part of the vascular system: very often - flushing of the face.
On the part of the skin and skin appendages: very often - sweating; often - rash, alopecia.
On the part of the musculoskeletal system: very often - joint and musculoskeletal pain.
Aromasin should not be given to women with premenopausal endocrine status, therefore, in cases where it is clinically justified, the postmenopausal status should be confirmed by determining the level of LH, FSH and estradiol.
Aromazine should not be administered simultaneously with drugs containing estrogen.
Store in a dry, dark place at a temperature not exceeding 25 ° C.
Aromazine